Answers are grounded in this paper and cite their sources.
Zanubrutinib may offer more favorable clinical outcomes with cost savings compared with ibrutinib for R/R CLL treatment from a US payer perspective. Additionally, cost savings could be realized from the Enhancing Oncology Care model, a value-based payment structure that incentivizes providers to deliver high-quality care while reducing overall health care spending.
No takes yet. Share an insight, caveat, or question.
Chanan‐Khan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: